BLA 761530 · Viridian Therapeutics INC
Lumvoa
Veligrotug-Vvze
NovelBreakthrough therapyPriority reviewCDER novel approval, Jun 26, 2026: To treat thyroid eye disease
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jun 26, 2026
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
5
4 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat thyroid eye disease
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Veligrotug" as an intervention, any sponsor and status, largest first.
- A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)Pivotal-lookingCompleted
Viridian Therapeutics, Inc.Industry
NCT06384547 · 231 participants · Start May 23, 2024 · Primary completion May 1, 2025
Drug: Veligrotug · For: Thyroid Eye Disease
Sites: Inglewood, California; Los Angeles, California; Palo Alto, California · 50 sites in all
- An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)Pivotal-lookingCompleted
Viridian Therapeutics, Inc.Industry
NCT06021054 · 188 participants · Start Nov 1, 2023 · Primary completion Nov 4, 2024
Drug: Veligrotug; Placebo · For: Thyroid Eye Disease
Sites: Los Angeles, California; Newport Beach, California; Palo Alto, California · 57 sites in all
- An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301Pivotal-lookingCompleted
Viridian Therapeutics, Inc.Industry
NCT06179875 · 139 participants · Start Jan 31, 2024 · Primary completion Apr 25, 2025
Drug: Veligrotug · For: Thyroid Eye Disease
Sites: Los Angeles, California; Newport Beach, California; Palo Alto, California · 45 sites in all
- A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)Pivotal-lookingCompleted
Viridian Therapeutics, Inc.Industry
NCT05176639 · 113 participants · Start Nov 16, 2022 · Primary completion Jul 15, 2024
Drug: Veligrotug; Placebo · For: Thyroid Eye Disease
Sites: Aurora, California; Beverly Hills, California; Los Angeles, California · 53 sites in all
- An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabNot yet recruiting
Viridian Therapeutics, Inc.Industry
NCT07832136 · 30 participants (planned) · Start Sep 2026 · Primary completion Apr 2027
Drug: veligrotrug (LUMVOA™) · For: Thyroid Eye Disease
Sites: Newport Beach, California; Sarasota, Florida; East Weymouth, Massachusetts · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.
Yen MT, Cockerham K, Saeed P, et al. · Ophthalmology 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Zhang H, Zhang Z, Lu T, et al. · Drugs 2026 · Systematic Review, Meta-Analysis
Sponsor: Viridian Therapeutics INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.